Company Overview
| Stock Name | Sirnaomics-B |
|---|---|
| Stock Code | 02257 |
| Company Full Name | To be extracted |
| Industry | Healthcare |
| Principal Activities | 我們是一家RNA療法生物製藥公司,候選產品處於臨床前及臨床階段,專注於探索及開發創新藥物,用於治療存在醫療需求及龐大市場機會的適應症。擁有專有的多肽納米顆粒(PNP)遞送平台及新型GalNAc RNAi遞送平台,核心產品STP705已在腫瘤學領域取得積極IIa期臨床結果。 |
| Listing Date | 2021-12-30 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | To be extracted |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 蘇州工業園星湖街218號A4樓415室 |
| Business Address (Hong Kong) | 香港灣仔皇后大道東183號合和中心46樓 |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | www.sirnaomics.com |
| Share Registrar | 香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited) |
| Registrar Contact | (852)2862 8628 |
| A-Share/US Dual Listing | No |
Offering Information
| Offering Mechanism | Mechanism A |
|---|---|
| Offer Price | HK$ 65.90 / shares |
| Offer Price Range | Final offer price only, no range |
| Lot Size | 50 shares |
| Entry Threshold | HK$ 3,295 |
| Par Value | RMB 0.001 / shares |
| Offer Period | 2021-12-20 to 2021-12-23 |
| Global Offering Shares | 7,540,000 shares |
| HK Public Offer Shares (Initial) | 754,000 shares (10.0%) |
| Public Offer Lots (Initial) | 15,080lots (Pool A7,540lots,Pool B7,540lots) |
| International Placing Shares (Initial) | 6,786,000 shares (90.0%) |
| Offer Ratio | ~10.0% |
| Total Shares Post-IPO | 88,066,780 shares |
| Greenshoe (Over-allotment Option) | Yes |
| Stabilizing Manager (Greenshoe) | To be extracted |
| Cornerstone Share | 44.9% |
| Clawback Tiers | To be extracted |
| Reallocation Option | No |
| Total Global Offering Size | HK$ 496,886,000 |
Subscription Tiers
Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.
Pool A
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 1 lots | 50 | HK$ 3,295 |
| 2 lots | 100 | HK$ 6,590 |
| 3 lots | 150 | HK$ 9,885 |
| 4 lots | 200 | HK$ 13,180 |
| 5 lots | 250 | HK$ 16,475 |
| 6 lots | 300 | HK$ 19,770 |
| 7 lots | 350 | HK$ 23,065 |
| 8 lots | 400 | HK$ 26,360 |
| 9 lots | 450 | HK$ 29,655 |
| 10 lots | 500 | HK$ 32,950 |
| 12 lots | 600 | HK$ 39,540 |
| 14 lots | 700 | HK$ 46,130 |
| 16 lots | 800 | HK$ 52,720 |
| 18 lots | 900 | HK$ 59,310 |
| 20 lots | 1,000 | HK$ 65,900 |
| 30 lots | 1,500 | HK$ 98,850 |
| 40 lots | 2,000 | HK$ 131,800 |
| 50 lots | 2,500 | HK$ 164,750 |
| 60 lots | 3,000 | HK$ 197,700 |
| 70 lots | 3,500 | HK$ 230,650 |
| 80 lots | 4,000 | HK$ 263,600 |
| 90 lots | 4,500 | HK$ 296,550 |
| 100 lots | 5,000 | HK$ 329,500 |
| 120 lots | 6,000 | HK$ 395,400 |
| 140 lots | 7,000 | HK$ 461,300 |
| 160 lots | 8,000 | HK$ 527,200 |
| 200 lots | 10,000 | HK$ 659,000 |
| 400 lots | 20,000 | HK$ 1,318,000 |
| 600 lots | 30,000 | HK$ 1,977,000 |
| 800 lots | 40,000 | HK$ 2,636,000 |
| 1,000 lots | 50,000 | HK$ 3,295,000 |
| 1,200 lots | 60,000 | HK$ 3,954,000 |
| 1,400 lots | 70,000 | HK$ 4,613,000 |
Pool B
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 1,800 lots | 90,000 | HK$ 5,931,000 |
| 2,000 lots | 100,000 | HK$ 6,590,000 |
| 4,000 lots | 200,000 | HK$ 13,180,000 |
| 7,540 lots | 377,000 | HK$ 24,844,300 |
Stock Connect Inclusion Analysis
| 26Q4 Regular Review | |
| Inclusion Pathway | Regular Path |
|---|---|
| HK Market Cap | HK$ 600.8M |
| Est. Threshold | HK$ 9.37B |
| Analysis Result | HK market cap below threshold, need +1460% |
Valuation & Financials
| Market Cap (at Offer Price) | HK$ 5,803,600,802 |
|---|---|
| Pre-IPO Valuation (Last Round) | Not disclosed |
| P/E Ratio | 不适用(公司处于亏损状态) |
| Profit/Loss Status | 亏损约46.4百万美元 |
| Period-End Cash Balance | 美元103.1百万元 |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | To be extracted |
Financial Data
Unit:
'000
USD
Income Statement
| Item | 2019 | 2020 | 5919 | 5920 | 5939 | 6920 | 7920 | 7939 |
|---|---|---|---|---|---|---|---|---|
| Profit before tax | -71,527 | -96,428 | ||||||
| Income tax expense | 0 | 0 | ||||||
| Profit for the year | -71,627 | -96,628 | ||||||
| Profit attributable to owners | -93,372 | -96,381 |
Income Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
| First Day Close | HK$ 77.9 |
|---|---|
| First Day Open | HK$ 65.9 |
| First Day Change | 18.21% |
| First Day Volume | 1252800.0 |
| First Day Turnover | 86073700.0 |
| Use of Proceeds | 1、約229.1百萬港元(相當于約29.4百萬美元,占所得款項凈額的57.9%)將用于撥付發展及商業化STP705;
2、約61.8百萬港元(相當于約7.9百萬美元,占所得款項凈額的15.6%)將用于撥付STP707的開發;
3、約60.7百萬港元(相當于約7.8百萬美元,占所得款項凈額的15.4%)將用于撥付我們的GalNAc計劃產品,以及其他臨床前階段候選產品;
4、約29.1百萬港元(相當于約3.7百萬美元,占所得款項凈額的7.3%)將用于撥付其他臨床前候選藥物的研發;
5、約15.0百萬港元(相當于約1.9百萬美元,占所得款項凈額的3.8%)將用于一般企業及營運資金用途。 |
Underwriting Syndicate
Sole Sponsor (1)
中国国际金融香港证券有限公司 CE AEN894
Overall Coordinators (5)
Joint Bookrunners (7)
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | 昆明佳时清投资合伙企业(有限合伙) | 183,956,555 HKD | — | 37.02% | — | 6 months | 2022-06-30 |
| 2 | 浙江健新原力制药有限公司 | 38,969,965 HKD | — | 7.84% | — | 6 months | 2022-06-30 |
Directors & Management
| Position | Chinese name | English Name |
|---|---|---|
| Chairman | 陸陽 | — |
| Company Secretary | 張蘊 | — |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 陸博士持股14.36%,戴曉暢博士持股9.42%(緊隨全球發售完成後,假設超額配股權未獲行使) |
|---|




